A carregar...
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. T...
Na minha lista:
| Publicado no: | BMC Neurol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6234796/ https://ncbi.nlm.nih.gov/pubmed/30413151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-018-1193-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|